Japan reimbursement approval reshapes Optune Lua access

NovoCure (NVCR) just received reimbursement approval in Japan for its Optune Lua device through the National Health Insurance, a regulatory milestone that widens access for eligible non small cell lung cancer patients.

For you as an investor, this decision ties product adoption directly to a large, insurance backed market. It adds a fresh piece of information to weigh against NovoCure's existing financial profile and share price performance.

The reimbursement news follows a fourth quarter where NovoCure reported US$174.35 million in sales and a smaller net loss, and provided 2026 revenue guidance alongside an ESOP related shelf registration. Despite a 14.12% 90 day share price return and 10.09% 30 day share price return, longer term total shareholder returns of 29.92% decline over one year and over 80% decline over three and five years point to momentum that is still rebuilding from a much lower base.

If this kind of cancer treatment story has your attention, it could be a good moment to look at other healthcare names using our screener of 31 healthcare AI stocks.

With the stock still well below its three and five year levels yet trading above recent lows, the key question for you is whether reimbursement and revenue guidance leave upside on the table or whether the market is already pricing in future growth.

Most Popular Narrative: 46.8% Undervalued

At a last close of $13.42 versus a fair value estimate of $25.21, the most followed narrative sees meaningful upside potential built into its assumptions.

Validation of TTFields therapy in multiple new indications, such as pancreatic cancer (PANOVA-3) and brain metastases from non-small cell lung cancer (METIS), positions NovoCure for potential regulatory approvals and large market expansion beginning in 2026, likely driving topline revenue growth as global cancer incidence rises in the aging population.

Curious what justifies almost doubling the current share price in that fair value? Revenue ramp assumptions, margin uplift, and a premium future earnings multiple all sit at the core of this narrative. However, the exact mix and timing are where the story gets interesting.

Result: Fair Value of $25.21 (UNDERVALUED)

However, you still need to weigh ongoing losses of US$136.227 million and concentration in a single TTFields platform, where trial setbacks or new competitors could quickly reshape expectations.

Another Angle on Value

Those fair value numbers lean heavily on future cash flows, but the current P/S of 2.3x tells a different story. NVCR trades cheaper than the US Medical Equipment average at 2.9x, yet richer than peers at 1.5x, and below a 4.2x fair ratio. Is that a bargain or a warning sign to you?

Next Steps

If this mix of risks and potential rewards feels finely balanced to you, move quickly to review the data yourself and weigh up 2 key rewards and 2 important warning signs.

Ready for more investment ideas?

If this news has sharpened your focus, do not stop here. Use the screeners below to look for other possibilities that may align with your strategy.

• Explore potential mispricings by scanning companies that our models flag as 47 high quality undervalued stocks based on quality and fundamentals.
• Review 14 dividend fortresses that may suit a yield focused portfolio.
• Filter for 77 resilient stocks with low risk scores that prioritize capital preservation while still offering potential for upside.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.